一种现成的一锅制备吡咯并[2,1- f ]-[1,2,4]三嗪和吡唑并[5,1- c ]嘧啶[4,5- e ]-[1,2,4]三嗪衍生品
摘要:
几种新的2,4-二取代的吡咯并[2,1- f ] [1,2,4]三嗪和吡唑并[5,1- c ]-嘧啶[4,5- e ] [1,2,4]三嗪N,N-二甲基二氯甲基亚甲基氯化铵与1-氨基吡咯-2-酮1和4-氨基-3-氰基吡唑乙基[5,1- c ] [1,2,4]三嗪-8-羧酸酯6的反应可轻松获得, 分别。
一种现成的一锅制备吡咯并[2,1- f ]-[1,2,4]三嗪和吡唑并[5,1- c ]嘧啶[4,5- e ]-[1,2,4]三嗪衍生品
摘要:
几种新的2,4-二取代的吡咯并[2,1- f ] [1,2,4]三嗪和吡唑并[5,1- c ]-嘧啶[4,5- e ] [1,2,4]三嗪N,N-二甲基二氯甲基亚甲基氯化铵与1-氨基吡咯-2-酮1和4-氨基-3-氰基吡唑乙基[5,1- c ] [1,2,4]三嗪-8-羧酸酯6的反应可轻松获得, 分别。
The present invention provides compounds of formula I
and pharmaceutically acceptable salts thereof.
The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2, FGFR-1, PDGFR, HER-1, HER-2, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.